Bayer's big investment in time and money on the development of finerenone for chronic kidney disease (CKD) in diabetics has paid off with an FDA approval, although it could face stiff competition ...

FINEARTS-HF is one of four phase 3 studies that Bayer is hoping to make finerenone a go-to therapy for heart failure patients, alongside the REDEFINE-HF trial of the drug as monotherapy in ...

In a recent study conducted by Navaneethan and colleagues and published in the International Society of Nephrology, the ...

In a recent study conducted by Sankar D Navaneethan and colleagues and published in the International Society of Nephrology, ...

Bayer AG BAYRY recently announced that the FDA had accepted its supplemental new drug application (sNDA) seeking approval for Kerendia (finerenone) to treat a new indication.The sNDA seeks ...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that data from 13 new analyses from across the KERENDIA® (finerenone) comprehensive clinical trial program will be presented at the American ...

selective mineralocorticoid receptor antagonist finerenone (Kerendia, Bayer), finerenone reduced risk for death, HF hospitalization and a composite of kidney-related endpoints compared with placebo.

A recent analysis compared the efficacy and safety of sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and finerenone (Kerendia; Bayer).

the cardiovascular and kidney benefits of Bayer’s Kerendia (finerenone) are maintained regardless of acute changes in estimated glomerular filtration rate (eGFR) following treatment initiation ...